First In Human By Vial

In this episode, Rachel Haines from Rinri Therapeutics joins us to discuss the possibilities of cell therapy for hearing loss. Our conversation with Rachel goes beyond just scientific innovation; we also explore the potential impact of Rinri's upcoming human trials, which are based on Professor Marcelo Rivolta's groundbreaking work. By delving into the challenges and excitement of pioneering clinical trials in uncharted territory, we envision a future where natural hearing restoration could become a reality. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Join as we dive deep into the world of oncology drug development with Bas van der Baan of Lixte. Discover the inspiration behind Lixte's focus on PP2A inhibitors and how this innovative approach is poised to revolutionize cancer treatment by enhancing chemotherapy and immunotherapy responses. Bas shares insights into ongoing clinical trials, regulatory considerations, and Lixte's ambitious long-term goals in expanding their impact on cancer care. Tune in to explore the cutting-edge science and vision driving Lixte's journey in the fight against cancer. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that's giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (MCOs), which have the potential to address all forms of retinal degeneration and restore vision in millions of visually impaired individuals. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Imagine unlocking the secrets to revitalizing the brain's energy centers and turning the tide on neurodegenerative diseases. In this episode, Rob introduces us to CNM-Au8, an oral nanotherapeutic with the potential to recharge failing mitochondria. Our discussion traverses the innovative path Clene has charted, from the drug's conception to the exciting clinical trial results that highlight its capacity to enhance neurological functions and offer new hope to individuals grappling with ALS and multiple sclerosis. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Step into the future as Dr. Jason Bock, founder and CEO of CTMC discusses the company's unique approach to accelerating cell therapies from development to testing, and the power of collaboration in reshaping the future of cancer treatment. Listen in as we discuss how CTMC's partnership with MD Anderson is not just technical but deeply human in nature, with the patient and personalized medicine at heart First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Embark on a quest to unravel the 'undruggable' genome with Alex Federation, Co-founder of Talus Bio. Explore challenges in targeting transcription factors in cancer with Talus's innovative Marmot platform. Discover potential breakthroughs in rare diseases and pediatric cancers, and glimpse into the future of studying transcription factors within live human cells. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Join Dr. Ahmed Hamdy, CEO of Vincerx Pharma, on a compelling journey through oncology. From co-founding Acerta Pharma to pioneering patient-centric innovations, Dr. Hamdy shares his impactful career. Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Have you ever considered the untapped potential of abandoned drugs? Join Dr. Sam Clark to discuss how his personal drive to combat mental illness is leading to breakthroughs in treatments for neurological and psychiatric diseases. Witness how Terran is not only resurrecting discarded medications for new purposes, but also pioneering the next generation of non-hallucinogenic psychedelic therapies aimed at tackling depression and Parkinson's psychosis. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Ever wondered how technology could drastically improve early detection in healthcare? Let us take you on a journey with Mark McDonough, President and CEO of ChromaCode, as we unfold the world of molecular diagnostics with a special focus on HDPCR technology. Mark, with his diverse background in the military and healthcare, brings a fresh perspective to the table. He shares his unique insights on leadership and the challenges that come with introducing ground-breaking technologies in a traditional industry. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Embark on a journey through the intricate world of biotech with Bogdan Kezevic, co-founder and CEO of Kaleidoscope Bio, and uncover the revolutionary software shaping the future of scientific research. Bogdan's leap from scientist to entrepreneur has led to groundbreaking solutions for the challenges plaguing biotech. In our chat, he shares how data mismanagement and a disconnect in collaboration can cripple research efforts. With Kaleidoscope's software, teams can now navigate the complexities of their work with tools designed for clarity and focus, ensuring that the intricacies of science are met with a user-friendly interface. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

What does it take to revolutionize the world of vaccines and touch lives across the globe? Join us on a riveting journey with Steven Reed, CEO and co-founder of HDT-Bio, as we explore the creation of the first refined tuberculosis vaccine and dive into the remarkable strides in RNA technology. This episode lifts the veil on the science that could redefine global health. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Join Jeffrey Bacha, a pioneer in the fight against cancer and the creative force behind Rakovina Therapeutics. For 25 years, Jeffrey has been reshaping the industry landscape, and today, he gives us a peek into his world of innovation. We venture into Rakovina's research and development of oncology drugs. exploring their groundbreaking technique combining PARP and HDAC inhibitors into a single molecule, a game-changer in enhancing synergy and reducing toxicity. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Embark on a fascinating exploration of biotech entrepreneurship, guided by an expert who's been in the trenches: Jonathan Thon, CEO and founder of STRM.BIO. We'll give you an insider's view of his journey from academia to the cutting edge of biotech, unveiling his trailblazing work on platelet production and the transformative potential of extracellular vesicles in gene therapy. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Ever wondered how far we've truly come in the realm of gene and cell therapies, and where we're headed next? This captivating conversation with Oscar Segurado, the CMO of ASC Therapeutics, will satisfy your curiosity. Oscar, a veteran in the biopharmaceutical industry, shares fascinating insights on ASC Therapeutics' groundbreaking innovation in personalized medicine and synthetic biology as they set out to redefine the future of therapies for rare diseases. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

We’re thrilled to share our enlightening exchange with Spiro Rombotis, the seasoned CEO of Cyclacel. He peels back the curtain on the breakthrough discovery of B53, a commonly mutated gene in cancer patients, and the inspiring success of FADRA, their lead drug in clinical trials. Furthermore, Spiro delves into the highs and lows faced by Cyclacel, including the triumphant moment a patient was declared cancer-free thanks to their groundbreaking drug. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Ever wondered about the people who are leading the fight against cancer, developing groundbreaking treatments, and changing lives? Meet Frank Boriello, the mind behind SUPLEXA cell therapy, and the CEO and founder of Alloplex Biotherapeutics. In our conversation, Frank shares the personal backstory that sparked his quest to revolutionize cancer treatment and frames the scientific journey that led to SUPLEXA. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Max Darnell, CEO and co-founder of Modulus Therapeutics, takes us through his thrilling journey from bioengineering and systems biology to launching a biotech startup. Max unveils how his team's curiosity and motivation, along with their high throughput discovery platform, are revolutionizing cell and cell therapy component designs. Hear how Modulus is making strides in the autoimmune space and harnessing the power of DNA barcoding and sequencing to transform traditional assays into high throughput screens. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Join 30-year industry veteran Pepper Landson, Co-founder and CEO of Praetego as she shares her inspiring journey that led her to tackle Alzheimer's and dementia through the innovative use of amadorins. Pepper's intriguing narrative not only highlights her commitment to the public health crisis surrounding these neurodegenerative diseases, but also the collateral damage they inflict on families and caregivers. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

Ever wonder how the complexities of gene therapies are addressed from bench to bedside? The creative solutions lie within the innovative approaches of seasoned professionals like Dr. Timothy Miller, Co-Founder, President, & CEO at Forge Biologics. With a fascinating career that interlaces academia, biotech, and entrepreneurship, Dr. Miller brings a wealth of knowledge to the realm of gene and cell therapy. Join us as we delve into the intricate machinery of Forge - from their pioneering cell line to their clinical-stage program. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials

What if your vision could be saved by the precise application of innovative biotech? Join us as we talk to David Esposito, President & CEO of ONL Therapeutics, and delve deep into his take on leadership. He shares how his military background has been instrumental in the successful management of clinical trials, particularly when navigating the unpredictable terrain of the COVID-19 pandemic. With their pipeline ONL1204, a FAS inhibitor targeting retinal disease, O&L Therapeutics is making significant strides in the ophthalmology space. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here. Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com. 🎧 Stay in the Loop! For the latest news and updates, visit our website: https://vial.com Follow us on social media for real-time insights: Twitter: https://twitter.com/VialTrials LinkedIn: https://www.linkedin.com/company/vialtrials